Menu Search
Equities

Summit Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
SMMT*:MEX

Summit Therapeutics Inc

Actions
  • Price (MXN)360.00
  • Today's Change0.00 / 0.00%
  • Shares traded785.00
  • 1 Year change-15.36%
  • Beta-1.4122
Data delayed at least 20 minutes, as of Oct 27 2025 11:30 BST.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.

  • Revenue in USD (TTM)0.00
  • Net income in USD-921.62m
  • Incorporated2020
  • Employees159.00
  • Location
    Summit Therapeutics Inc601 Brickell Key Drive, Suite 1000MIAMI 33131United StatesUSA
  • Phone+1 (305) 203-2034
  • Fax+1 (302) 655-5049
  • Websitehttps://www.smmttx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.